Searched over 200M research papers for "bronchodilator inhaler"
10 papers analyzed
These studies suggest that bronchodilator inhalers, including metered dose inhalers and combination therapies, are effective for treating COPD and asthma, with specific devices and techniques varying in efficiency and suitability for different patient groups.
20 papers analyzed
Bronchodilator inhalers are essential in managing chronic obstructive pulmonary disease (COPD) and asthma. These devices deliver medication directly to the lungs, helping to open airways and ease breathing. Various types of inhalers, including long-acting β-agonists (LABA), long-acting muscarinic antagonists (LAMA), and combinations of these with inhaled corticosteroids (ICS), are used to control symptoms and prevent exacerbations.
A comprehensive review of 99 studies involving 101,311 participants with moderate to severe COPD found that LABA/LAMA combinations are the most effective in reducing COPD exacerbations compared to other inhaler types. Specifically, LABA/LAMA combinations significantly decreased moderate to severe exacerbations compared to LABA/ICS combinations, LAMA, and LABA alone in high-risk populations. Additionally, LAMA inhalers were more effective than LABA inhalers in reducing exacerbations in both high- and low-risk populations.
Combination therapies, particularly LABA/LAMA, also showed a trend towards better symptom control and quality of life improvements compared to monotherapies. However, LABA/ICS combinations were associated with a higher risk of pneumonia, making them less favorable in terms of safety.
In mechanically ventilated patients, MDIs have been shown to be as effective as nebulizers for delivering bronchodilators like albuterol. Both methods resulted in similar improvements in pulmonary function, with MDIs offering a cost-effective alternative. Additionally, the use of an end-inspiratory pause did not significantly enhance the bronchodilation effect of MDIs in these patients.
A study comparing different actuator devices for MDIs in ventilated patients found that devices with holding chambers were more effective in delivering medication to the lungs than those without. This suggests that the choice of actuator device can impact the efficiency of bronchodilator delivery in mechanically ventilated patients.
For non-acute asthma, pMDIs are as effective as other handheld inhaler devices for delivering short-acting β-agonists (SABAs). Regular use of HFA-pMDIs containing salbutamol was found to reduce the need for short courses of oral corticosteroids, although the total number of exacerbations remained unchanged.
In children with acute asthma exacerbations, SABAs delivered by MDIs with spacers were effective in reducing hospital admissions and emergency department length of stay. The use of valved holding chambers with masks also proved to be a reliable method for administering bronchodilators to young children.
Despite the efficacy of various inhaler devices, patient errors in using devices like soft mist inhalers (SMIs) are common. A meta-analysis revealed that about 59% of patients made at least one device use error, highlighting the need for individualized device selection and ongoing training to optimize treatment outcomes.
Bronchodilator inhalers, particularly LABA/LAMA combinations, are highly effective in managing COPD by reducing exacerbations and improving quality of life. In mechanically ventilated patients, MDIs are a viable alternative to nebulizers, especially when used with appropriate actuator devices. For asthma management, pMDIs are as effective as other devices, and proper training is crucial to minimize device use errors and ensure effective medication delivery.
Most relevant research papers on this topic